Bioequivalence and Bioavailability Forum 00:36 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Fampridine [Design Issues]

posted by MaggieSantos - Portugal, 2017-09-20 13:05  - Posting: # 17821
Views: 1,928

Good morning,

We have been asked to perform a BE study on Fampridine.

I would like to confirm two informations. Does Fampridine is considered a NTI drug for EMA?

Considering a CI limit of 90-111% whats the recomende sample size for fampridine.

Do you know any good and free calculation site for BE?

Kind Regards

mMrgarida Barreto

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,697 posts in 3,982 threads, 1,237 registered users;
online 13 (0 registered, 13 guests [including 13 identified bots]).

Science should always be the basis
of regulatory requirements.    Joachim Röhmel

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed